First prescription eye drop in its class to receive a first-line indication for use in those with ocular hypertension and the most common form of glaucoma
Pharmacia Corporation (NYSE: PHA) announced today that the U.S. Food and Drug Administration (FDA) has approved the once-daily prescription eye drop Xalatan® (latanoprost ophthalmic solution) as an initial treatment for elevated eye pressure associated with open-angle glaucoma or ocular hypertension. Xalatan is the first and only prostaglandin with a first-line indication for the treatment of elevated eye pressure (intraocular pressure or IOP) in all three major markets: the United States, Europe and Japan.
“The first-line indication supports the use of Xalatan earlier in the treatment process,” said Robert Fechtner, M.D., Professor of Ophthalmology and Director of the Glaucoma Division, UMDNJ-New Jersey Medical School. “Effective first-line treatment becomes even more important in light of recent studies that have further emphasized the importance of early treatment. Elevated IOP represents a major risk factor for vision loss with glaucoma; the higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!